PT  - JOURNAL ARTICLE
AU  - Huilei Zhao
AU  - Shanshan Huang
AU  - Kaibo Mei
AU  - Wen Shao
AU  - Jing Zhang
AU  - Jianyong Ma
AU  - Wengen Zhu
AU  - Yuan Jiang
AU  - Peng Yu
AU  - Xiao Liu
TI  - Prevalence use of nonsteroidal anti-inflammatory drugs in the general population with COVID-19 and associated COVID-19 risk, hospitalization, severity, death, and safety outcomes: A systematic review and meta-analysis
AID  - 10.1101/2021.05.01.21256428
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.01.21256428
4099  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256428.short
4100  - http://medrxiv.org/content/early/2021/05/05/2021.05.01.21256428.full
AB  - Introduction Recent reports of potential harmful effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with Corona Virus Disease 2019 (COVID-19) have provoked great concern. Therefore, the safety of NSAIDs is still questioned.Methods We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases from December 2019 to January 2021 to examine use prevalence for NSAIDs in general, as well as associated COVID-19 risk and outcomes. This study has been registered with PROSPERO (CRD42019132063)Results We included 25 studies with a total of 101,215 COVID-19 patients. The use of NSAIDs in COVID-19 patients reached 19%. Exposure to NSAIDs was not associated with significantly increased risk of developing COVID-19 (odds ratio [OR]=0.98, 95% confidence interval [CI]: 0.78-1.24; I2=82%), hospitalization (OR=1.06, 95%CI: 0.76-1.48; I2=81%), mechanical ventilation (OR=0.71, 95%CI: 0.47-1.06; I2=38%), and length of hospital stay. Moreover, use of NSAIDs was significantly associated with better outcomes, including severity of COVID-19 (OR=0.79, 95%CI: 71-0.89; I2=0%) and death (OR=0.68, 95%CI: 0.52-0.89; I2=85%) in patients with COVID-19. Regarding safety outcomes, exposure to NSAIDs was associated with increased risk of stroke (OR=2.32, 95%CI: 1.04-5.2; I2=0%), but not with myocardial infraction (OR=1.49; p=0.66; I2=0%), overt thrombosis (OR=0.76, p=0.50; I2=28%) and major bleeding (p=0.61).Conclusion Based on current evidence, exposure to NSAIDs is not linked to increased odds or exacerbation of COVID-19 in the general COVID-19 population. Furthermore, administration of NSAIDs might have better outcomes and survival benefits in the general COVID-19 population, although potentially increasing the risk of stroke. Use of NSAIDs might be safe and beneficial in COVID-19. Future observational and randomized control trials are needed for further confirmation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Natural Science Foundation of China (P-Y, 81760050, 81760048) and the Jiangxi Provincial Natural Science Foundation for Youth Scientific Research (P-Y, 20192ACBL21037). Young Teachers' Basic Scientific Research Business Expenses Project (W.G-Z, 20ykpy72); China Postdoctoral Science Foundation (W.G-Z,2020M673016); China National Postdoctoral Program for Innovative Talents (W.G-Z, BX20200400). Guangdong Medical Science and Technology Research Foundation (Y-J, A2021006); Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article [and its supplementary information files].